Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595
In the original publication [...]
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/6/858 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850165095360888832 |
|---|---|
| author | Nicola Sgherza Olga Battisti Paola Curci Concetta Conticello Salvatore Palmieri Daniele Derudas Candida Germano Enrica Antonia Martino Giuseppe Mele Roberta Della Pepa Francesca Fazio Anna Mele Bernardo Rossini Giulia Palazzo Daniela Roccotelli Simona Rasola Maria Teresa Petrucci Domenico Pastore Giuseppe Tarantini Fabrizio Pane Massimo Gentile Francesco Di Raimondo Emanuela Resta Pellegrino Musto |
| author_facet | Nicola Sgherza Olga Battisti Paola Curci Concetta Conticello Salvatore Palmieri Daniele Derudas Candida Germano Enrica Antonia Martino Giuseppe Mele Roberta Della Pepa Francesca Fazio Anna Mele Bernardo Rossini Giulia Palazzo Daniela Roccotelli Simona Rasola Maria Teresa Petrucci Domenico Pastore Giuseppe Tarantini Fabrizio Pane Massimo Gentile Francesco Di Raimondo Emanuela Resta Pellegrino Musto |
| author_sort | Nicola Sgherza |
| collection | DOAJ |
| description | In the original publication [...] |
| format | Article |
| id | doaj-art-f04dae20d2e549d1baa8f1906a8d834f |
| institution | OA Journals |
| issn | 1424-8247 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj-art-f04dae20d2e549d1baa8f1906a8d834f2025-08-20T02:21:49ZengMDPI AGPharmaceuticals1424-82472025-06-0118685810.3390/ph18060858Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595Nicola Sgherza0Olga Battisti1Paola Curci2Concetta Conticello3Salvatore Palmieri4Daniele Derudas5Candida Germano6Enrica Antonia Martino7Giuseppe Mele8Roberta Della Pepa9Francesca Fazio10Anna Mele11Bernardo Rossini12Giulia Palazzo13Daniela Roccotelli14Simona Rasola15Maria Teresa Petrucci16Domenico Pastore17Giuseppe Tarantini18Fabrizio Pane19Massimo Gentile20Francesco Di Raimondo21Emanuela Resta22Pellegrino Musto23Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, 70124 Bari, ItalyHematology and Stem Cell Transplantation Unit, AOUC Policlinico, 70124 Bari, ItalyHematology and Stem Cell Transplantation Unit, AOUC Policlinico, 70124 Bari, ItalyDivision of Hematology and Stem Cell Transplantation, Policlinico “G. Rodolico-San Marco”, 95123 Catania, ItalyHematology Unit, Ospedale Cardarelli, 80131 Napoli, ItalyDepartment of Hematology, Businco Hospital, 09121 Cagliari, ItalyHematology Unit, “Dimiccoli” Hospital, 70051 Barletta, ItalyDepartment of Onco-Hematology, Hematology Unit, Azienda Ospedaliera Annunziata, 87100 Cosenza, ItalyHematology Unit, “Perrino” Hospital, 72100 Brindisi, ItalyHematology—Department of Clinical Medicine and Surgery, University Hospital “Federico II”, 80131 Napoli, ItalyDepartment of Translational and Precision Medicine Hematology, Sapienza University, 00185 Roma, ItalyHematology Unit, “Cardinale Panico” Hospital, 70039 Tricase, ItalyHematology and Cell Therapy Unit, IRCCS Istituto Tumori “Giovanni Paolo II” Bari, 70124 Bari, ItalyHaematology Unit, Ospedale G. Moscati, 74010 Taranto, ItalyDepartment of Hematology and Bone Marrow Transplant, IRCSS “Casa Sollievo Della Sofferenza”, 71013 Foggia, ItalyDepartment of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine, 70121 Bari, ItalyDepartment of Translational and Precision Medicine Hematology, Sapienza University, 00185 Roma, ItalyHematology Unit, “Perrino” Hospital, 72100 Brindisi, ItalyHematology Unit, “Dimiccoli” Hospital, 70051 Barletta, ItalyHematology—Department of Clinical Medicine and Surgery, University Hospital “Federico II”, 80131 Napoli, ItalyDepartment of Onco-Hematology, Hematology Unit, Azienda Ospedaliera Annunziata, 87100 Cosenza, ItalyDivision of Hematology and Stem Cell Transplantation, Policlinico “G. Rodolico-San Marco”, 95123 Catania, ItalyDepartment of Clinical and Molecular Medicine, Sapienza University, 00185 Roma, ItalyHematology and Stem Cell Transplantation Unit, AOUC Policlinico, 70124 Bari, ItalyIn the original publication [...]https://www.mdpi.com/1424-8247/18/6/858n/a |
| spellingShingle | Nicola Sgherza Olga Battisti Paola Curci Concetta Conticello Salvatore Palmieri Daniele Derudas Candida Germano Enrica Antonia Martino Giuseppe Mele Roberta Della Pepa Francesca Fazio Anna Mele Bernardo Rossini Giulia Palazzo Daniela Roccotelli Simona Rasola Maria Teresa Petrucci Domenico Pastore Giuseppe Tarantini Fabrizio Pane Massimo Gentile Francesco Di Raimondo Emanuela Resta Pellegrino Musto Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595 Pharmaceuticals n/a |
| title | Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595 |
| title_full | Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595 |
| title_fullStr | Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595 |
| title_full_unstemmed | Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595 |
| title_short | Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. <i>Pharmaceuticals</i> 2025, <i>18</i>, 595 |
| title_sort | correction sgherza et al efficacy and safety of isatuximab carfilzomib and dexamethasone isakd in multiple myeloma patients at the first relapse after autologous stem cell transplantation and lenalidomide maintenance results from the multicenter real life aeneid study i pharmaceuticals i 2025 i 18 i 595 |
| topic | n/a |
| url | https://www.mdpi.com/1424-8247/18/6/858 |
| work_keys_str_mv | AT nicolasgherza correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT olgabattisti correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT paolacurci correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT concettaconticello correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT salvatorepalmieri correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT danielederudas correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT candidagermano correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT enricaantoniamartino correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT giuseppemele correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT robertadellapepa correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT francescafazio correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT annamele correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT bernardorossini correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT giuliapalazzo correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT danielaroccotelli correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT simonarasola correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT mariateresapetrucci correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT domenicopastore correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT giuseppetarantini correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT fabriziopane correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT massimogentile correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT francescodiraimondo correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT emanuelaresta correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 AT pellegrinomusto correctionsgherzaetalefficacyandsafetyofisatuximabcarfilzomibanddexamethasoneisakdinmultiplemyelomapatientsatthefirstrelapseafterautologousstemcelltransplantationandlenalidomidemaintenanceresultsfromthemulticenterreallifeaeneidstudyipharmaceuticalsi2025i1 |